Triple test Triple test The triple test, also called triple screen, the Kettering test or the Bart's test, is an investigation performed during pregnancy in the second trimester to classify a patient as either high-risk or low-risk for chromosomal abnormalities (and neural tube defects). The term "multiple-marker screening test" is sometimes used instead. This term can encompass the "double test" and "quadruple test" (described below). The Triple screen measures serum levels of AFP, estriol, and beta-hCG, with a 70% sensitivity and 5% false-positive rate. It is complemented in some regions of the United States, as the "Quad screen" (adding inhibin A to
Double beta decay or double beta decay are predicted to be very long; hence, quadruple beta decay is unlikely to be realized. The eight candidate nuclei for quadruple beta decay include Zr, Xe, and Nd capable of quadruple beta-minus decay, and Xe, Ba, Gd, and Dy capable of quadruple beta-plus decay or electron capture. In theory, quadruple beta decay may be experimentally observable in three of these nuclei, with the most promising candidate being Nd. Double beta decay In nuclear physics, double beta decay is a type of radioactive decay in which two neutrons are simultaneously transformed into two protons, or vice versa,